Literature DB >> 16548452

Anemia in chronic kidney disease: causes, diagnosis, treatment.

Saul Nurko1.   

Abstract

Most patients with chronic kidney disease eventually become anemic. We should view the management of anemia in these patients as part of the overall management of the many clinically relevant manifestations of chronic kidney disease. Erythropoiesis-stimulating agents (ESAs) are safe and should be used, as treating anemia may forestall some of the target-organ damage of chronic kidney disease.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16548452     DOI： 10.3949/ccjm.73.3.289

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  30 in total

1.  Anemia in patients on chronic hemodialysis in Cameroon: prevalence, characteristics and management in low resources setting.

Authors:  Francois Folefack Kaze; Andre-Pascal Kengne; Alex Tatang Mambap; Marie-Patrice Halle; Dora Mbanya; Gloria Ashuntantang
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

2.  Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?

Authors:  Luca Di Lullo; Fulvio Floccari; Antonio Granata; Moreno Malaguti
Journal:  Cardiorenal Med       Date:  2011-12-16       Impact factor: 2.041

3.  Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease.

Authors:  Gjin Ndrepepa; Franz-Josef Neumann; Salvatore Cassese; Massimiliano Fusaro; Ilka Ott; Stefanie Schulz; Petra Hoppmann; Gert Richardt; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2013-10-04       Impact factor: 5.460

4.  Cost of managing anemia in end-stage renal disease: the experience of five French dialysis centers.

Authors:  Jacques Rottembourg; Patrick Tilleul; Gilbert Deray; Antoine Lafuma; Lorraine Zakin; Lamine Mahi; Jorge Wernli
Journal:  Eur J Health Econ       Date:  2014-02-26

5.  Anemia is independently associated with NT-proBNP levels in asymptomatic predialysis patients with chronic kidney disease.

Authors:  B Tirmenstajn-Jankovic; N Dimkovic; G Perunicic-Pekovic; Z Radojicic; D Bastac; S Zikic; M Zivanovic
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

Review 6.  The role of anemia management in improving outcomes for African-Americans with chronic kidney disease.

Authors:  Janice P Lea; Keith Norris; Lawrence Agodoa
Journal:  Am J Nephrol       Date:  2008-04-24       Impact factor: 3.754

7.  The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure.

Authors:  Yossi Chait; Sahir Kalim; Joseph Horowitz; Christopher V Hollot; Elizabeth D Ankers; Michael J Germain; Ravi I Thadhani
Journal:  Hemodial Int       Date:  2016-02-03       Impact factor: 1.812

8.  Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.

Authors:  Louis Holdstock; Amy M Meadowcroft; Rayma Maier; Brendan M Johnson; Delyth Jones; Anjay Rastogi; Steven Zeig; John J Lepore; Alexander R Cobitz
Journal:  J Am Soc Nephrol       Date:  2015-10-22       Impact factor: 10.121

9.  Dietary Micronutrients and Risk of Chronic Kidney Disease: A Cohort Study with 12 Year Follow-Up.

Authors:  Juyeon Lee; Kook-Hwan Oh; Sue-Kyung Park
Journal:  Nutrients       Date:  2021-04-30       Impact factor: 5.717

10.  Is There a Gender Difference in Clinical Presentation of Renal Hyperparathyroidism and Outcome after Parathyroidectomy?

Authors:  Claudia Bures; Tatjana Skachko; Eva M Dobrindt; Johann Pratschke; Deniz Uluk; Martina T Mogl
Journal:  Visc Med       Date:  2020-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.